152 related articles for article (PubMed ID: 23541745)
1. In silico modeling to predict drug-induced phospholipidosis.
Choi SS; Kim JS; Valerio LG; Sadrieh N
Toxicol Appl Pharmacol; 2013 Jun; 269(2):195-204. PubMed ID: 23541745
[TBL] [Abstract][Full Text] [Related]
2. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Kruhlak NL; Choi SS; Contrera JF; Weaver JL; Willard JM; Hastings KL; Sancilio LF
Toxicol Mech Methods; 2008; 18(2-3):217-27. PubMed ID: 20020916
[TBL] [Abstract][Full Text] [Related]
3. Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities.
Valerio LG; Cross KP
Toxicol Appl Pharmacol; 2012 May; 260(3):209-21. PubMed ID: 22426359
[TBL] [Abstract][Full Text] [Related]
4. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
[TBL] [Abstract][Full Text] [Related]
5. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays.
Mesens N; Steemans M; Hansen E; Verheyen GR; Van Goethem F; Van Gompel J
Toxicol In Vitro; 2010 Aug; 24(5):1417-25. PubMed ID: 20430096
[TBL] [Abstract][Full Text] [Related]
6. A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities.
Valencia A; Prous J; Mora O; Sadrieh N; Valerio LG
Toxicol Appl Pharmacol; 2013 Dec; 273(3):427-34. PubMed ID: 24090816
[TBL] [Abstract][Full Text] [Related]
7. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Fischer H; Atzpodien EA; Csato M; Doessegger L; Lenz B; Schmitt G; Singer T
J Med Chem; 2012 Jan; 55(1):126-39. PubMed ID: 22122484
[TBL] [Abstract][Full Text] [Related]
8. Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach.
Bauch C; Bevan S; Woodhouse H; Dilworth C; Walker P
Toxicol In Vitro; 2015 Apr; 29(3):621-30. PubMed ID: 25668432
[TBL] [Abstract][Full Text] [Related]
9. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
[TBL] [Abstract][Full Text] [Related]
10. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
11. Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds.
Orogo AM; Choi SS; Minnier BL; Kruhlak NL
Mol Inform; 2012 Oct; 31(10):725-39. PubMed ID: 27476455
[TBL] [Abstract][Full Text] [Related]
12. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Prado-Prado FJ; Martinez de la Vega O; Uriarte E; Ubeira FM; Chou KC; González-Díaz H
Bioorg Med Chem; 2009 Jan; 17(2):569-75. PubMed ID: 19112024
[TBL] [Abstract][Full Text] [Related]
13. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
[TBL] [Abstract][Full Text] [Related]
14. Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities.
Frid AA; Matthews EJ
Regul Toxicol Pharmacol; 2010 Apr; 56(3):276-89. PubMed ID: 19941924
[TBL] [Abstract][Full Text] [Related]
15. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
[TBL] [Abstract][Full Text] [Related]
16. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
[TBL] [Abstract][Full Text] [Related]
17. Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis.
Kuroda Y; Saito M
Toxicol In Vitro; 2010 Mar; 24(2):661-8. PubMed ID: 19786086
[TBL] [Abstract][Full Text] [Related]
18. Critically Assessing the Predictive Power of QSAR Models for Human Liver Microsomal Stability.
Liu R; Schyman P; Wallqvist A
J Chem Inf Model; 2015 Aug; 55(8):1566-75. PubMed ID: 26170251
[TBL] [Abstract][Full Text] [Related]
19. Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment.
Liu N; Tengstrand EA; Chourb L; Hsieh FY
Toxicol Appl Pharmacol; 2014 Sep; 279(3):467-476. PubMed ID: 24967688
[TBL] [Abstract][Full Text] [Related]
20. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
